Denmark · Delayed Price · Currency is DKK ChemoMetec Statistics
Total Valuation
ChemoMetec has a market cap or net worth of DKK 8.86 billion. The enterprise value is 8.57 billion.
| Market Cap | 8.86B |
| Enterprise Value | 8.57B |
Important Dates
The last earnings date was Thursday, September 10, 2026.
| Earnings Date | Sep 10, 2026 |
| Ex-Dividend Date | Oct 10, 2025 |
Share Statistics
ChemoMetec has 17.20 million shares outstanding. The number of shares has decreased by -0.03% in one year.
| Current Share Class | 17.20M |
| Shares Outstanding | 17.20M |
| Shares Change (YoY) | -0.03% |
| Shares Change (QoQ) | -0.05% |
| Owned by Insiders (%) | 4.22% |
| Owned by Institutions (%) | 31.42% |
| Float | 16.48M |
Valuation Ratios
The trailing PE ratio is 44.40 and the forward PE ratio is 41.20.
| PE Ratio | 44.40 |
| Forward PE | 41.20 |
| PS Ratio | 17.33 |
| PB Ratio | 12.21 |
| P/TBV Ratio | 17.13 |
| P/FCF Ratio | 48.66 |
| P/OCF Ratio | 42.11 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 32.23, with an EV/FCF ratio of 47.07.
| EV / Earnings | 42.46 |
| EV / Sales | 16.77 |
| EV / EBITDA | 32.23 |
| EV / EBIT | 34.14 |
| EV / FCF | 47.07 |
Financial Position
The company has a current ratio of 4.09, with a Debt / Equity ratio of 0.01.
| Current Ratio | 4.09 |
| Quick Ratio | 3.06 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | 0.02 |
| Debt / FCF | 0.03 |
| Interest Coverage | 641.93 |
Financial Efficiency
Return on equity (ROE) is 28.56% and return on invested capital (ROIC) is 44.96%.
| Return on Equity (ROE) | 28.56% |
| Return on Assets (ROA) | 18.45% |
| Return on Invested Capital (ROIC) | 44.96% |
| Return on Capital Employed (ROCE) | 34.26% |
| Weighted Average Cost of Capital (WACC) | 11.91% |
| Revenue Per Employee | 2.94M |
| Profits Per Employee | 1.16M |
| Employee Count | 174 |
| Asset Turnover | 0.60 |
| Inventory Turnover | 0.20 |
Taxes
In the past 12 months, ChemoMetec has paid 56.34 million in taxes.
| Income Tax | 56.34M |
| Effective Tax Rate | 21.82% |
Stock Price Statistics
The stock price has decreased by -19.34% in the last 52 weeks. The beta is 1.39, so ChemoMetec's price volatility has been higher than the market average.
| Beta (5Y) | 1.39 |
| 52-Week Price Change | -19.34% |
| 50-Day Moving Average | 472.32 |
| 200-Day Moving Average | 456.78 |
| Relative Strength Index (RSI) | 56.24 |
| Average Volume (20 Days) | 85,217 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, ChemoMetec had revenue of DKK 511.06 million and earned 201.84 million in profits. Earnings per share was 11.60.
| Revenue | 511.06M |
| Gross Profit | 485.99M |
| Operating Income | 251.00M |
| Pretax Income | 258.17M |
| Net Income | 201.84M |
| EBITDA | 265.88M |
| EBIT | 251.00M |
| Earnings Per Share (EPS) | 11.60 |
Balance Sheet
The company has 293.56 million in cash and 4.59 million in debt, with a net cash position of 288.97 million or 16.80 per share.
| Cash & Cash Equivalents | 293.56M |
| Total Debt | 4.59M |
| Net Cash | 288.97M |
| Net Cash Per Share | 16.80 |
| Equity (Book Value) | 725.39M |
| Book Value Per Share | 41.94 |
| Working Capital | 396.56M |
Cash Flow
In the last 12 months, operating cash flow was 210.36 million and capital expenditures -28.31 million, giving a free cash flow of 182.05 million.
| Operating Cash Flow | 210.36M |
| Capital Expenditures | -28.31M |
| Depreciation & Amortization | 14.88M |
| Net Borrowing | 266,000 |
| Free Cash Flow | 182.05M |
| FCF Per Share | 10.58 |
Margins
Gross margin is 95.10%, with operating and profit margins of 49.11% and 39.49%.
| Gross Margin | 95.10% |
| Operating Margin | 49.11% |
| Pretax Margin | 50.52% |
| Profit Margin | 39.49% |
| EBITDA Margin | 52.02% |
| EBIT Margin | 49.11% |
| FCF Margin | 35.62% |
Dividends & Yields
This stock pays an annual dividend of 7.00, which amounts to a dividend yield of 1.36%.
| Dividend Per Share | 7.00 |
| Dividend Yield | 1.36% |
| Dividend Growth (YoY) | 75.00% |
| Years of Dividend Growth | 1 |
| Payout Ratio | 60.35% |
| FCF Payout Ratio | 66.14% |
| Buyback Yield | 0.03% |
| Shareholder Yield | 1.38% |
| Earnings Yield | 2.28% |
| FCF Yield | 2.06% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Analyst Forecast
The average price target for ChemoMetec is 635.00, which is 23.30% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | 635.00 |
| Price Target Difference | 23.30% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (3Y) | 16.70% |
| EPS Growth Forecast (3Y) | 19.31% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
ChemoMetec has an Altman Z-Score of 44.07 and a Piotroski F-Score of 6.
| Altman Z-Score | 44.07 |
| Piotroski F-Score | 6 |